Go or no go? Sarepta’s gene therapy faces scrutiny
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Conditions are ripe for reverse mergers
Redx makes the most of Jounce’s demise, but is the poor reputation of reverse mergers warranted?
A renewed push into early bladder cancer
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.
Fate runs out of excuses
The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.
Cytokine players keep the faith
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Cytokine interest shows no sign of waning
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
